Synthesis and In vitro Cytotoxic Evaluation of New Quinazolinone-Based Chalcones
Main Article Content
Abstract
Cancer is currently a global concern and considered to be the cause of the high death rate in recent decades. Despite of advancement in cancer chemotherapy, the successful treatment of cancer remains a significant challenge because of the drug resistance and adverse side effects of chemotherapy. The search for new compounds as more effective and reliable anticancer agents is urgent. Chalcones are a class of compounds with a wide range of biological activities. In addition, derivatives based on the quinazolinone skeleton are currently of interest to research in the screening of compounds with cytotoxic effects. Compounds containing chalcone structures on the basis of quinazolinone can yield new structures with cytotoxic effects. This article presents the synthesis of new quinazolinone-based chalcones 8a-j via a three step-procedure. The first step is the condensation of 5-hydroxyanthranilic acid (5) with acetic anhydride at reflux for 2 h to afford intermediate 6 in 87%. This intermediate was then reacted with 4-aminoacetophenone in acetic acid at reflux for 14 h to give 7 in 77 %. Finally, the reaction of 7 with different aldehydes in ethanol in the presence of NaOH at room temperature for 14 h furnished target compounds 8a-j in 57 – 75 %. The structure of synthesized compounds was confirmed using 1H, 13C NMR and MS spectra. The bioassay results showed that several compounds displayed cytotoxic activity against two cell lines including HepG-2 and SKLu-1. Among synthesized compounds, 8c exhibited the strongest cytotoxic activity against SKLu-1 with IC50 value of 8.04 µg/mL.
Keywords
cancer, chalcone, cytotoxicity, quinazolinone
Article Details
References
[1]. Y. Ouyang, J. Li, X Chen, Xiaoyu, S. Sun and Q. Wu, Chalcone derivatives: role in anticancer therapy, Biomolecules., vol. 11, no. 06, June. 2021, Art. No 10.3390. https://doi.org/10.3390/biom1106089.
[2]. K. Higuchi, T. Watanabe, T. Tanigawa, Tominaga, K. Fujiwara, Y. Arakawa, T. Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori: A randomized controlled comparative trial with cimetidine, an H2-receptor antagonist, J. Gastroenterol. Hepatol., vol. 25, no. 01, April. 2010, Art. No S155. https://doi.org/10.1111/j.1440-1746.2010.06232.x
[3]. D. J. Connolly, D. Cusack, T. P. O’Sullivan and P. J. Guiry, Synthesis of quinazoliones and quinazolines, Tetrahedron., vol. 61, no. 43, October. 2005, Art. No 10153. http://dx.doi.org/10.1016/j.tet.2005.07.010
[4]. R. Rajput, A. P. Mishar, A review on biological activity of quinazoliones, Acadamic Sciences., vol. 04, no. 02. Janu. 2012, Art. No 66.
[5]. M. R Yadav, P. P. Naik, H. P. Gandhi, B. S. Chauhan, R. Giridhar, Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism, Bioorg. Med. Chem. Lett., vol. 23, no. 13, July. 2013, Art. No 3959. https://doi.org/10.1016/j.bmcl.2013.04.054
[6]. A. Hameed, M. Al-Rashida, M. Uroos, S. A. Ali, Arshia, M. Ishtiaq, K. M. Khan, Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016)- Expert Opin, Ther. Pat., vol. 28, no. 04, Feb. 2018, Art. No 281. https://doi.org/10.1080/13543776.2018.1432596.
[7]. T. P. Selvam, P. V. Kumar, Quinazoline marketed drugs, Res. Pharm., vol. 01, no. 01, 2015, Art. No 1-121.
[8]. P. N. Abida, M. Arpanarana, An updated review: newer quinazoline derivatives under clinical trial, Int. J. Pharm. Biol. Sci. Arch., vol. 02, no. 06, 2011, Art. No 1651.
[9]. A. W. Zahoor, S. P. Anup, M. Girish, B. Akanksha, J. M. Mubashir, K. G. Santosh, A. Viswanath, M. Fayaz, K. Ahmed, M. M. Dilip, Anticancer activity of a novel quinazolinone-chalcone derivative through cell cycle arrest in pancreatic cancer cell line. J. Solid Tumors., vol. 05, no. 02, June. 2015, Art. No 73. https://doi.org/10.5430/jst.v5n2p73
[10]. A W. Zahoor , K. G. Santosh, A.V. Subba, S. Sonia, M. Girish, B. Akanksha, K. Ashok, P. R. Sharma, K. Ahmed, B. Shashi, A novel quinazolinone chalcone derivative induces mitochondrial dependent apoptosis and inhibits PI3K/Akt/mTOR signaling pathway in human colon cancer HCT116 cells. Food Chem. Toxicol., vol. 87, Jan. 2016, Art. No 1. https://doi.org/10.1016/j.fct.2015.11.016
[11]. Nguyen V. Minh, Nguyen T. Thanh, Hoang T. Lien, Dinh T.P. Anh, Ho D. Cuong, Nguyen H. Nam, Pham T. Hai, Le Minh-Ngoc, Huong Le-Thi-Thu, Luu V. Chinh and Tran K. Vu. Design, Synthesis and Biological Evaluation of Novel Nhydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and cytotoxic agents. Anticancer Agents Med Chem., vol. 19, no. 12, Agust. 2019, Art. No 1543. https://doi.org/10.2174/1871520619666190702142654
[12]. P. Skehan, D. Storeng, A. Scudiero, J. Monks, D. McMahon, J. T. Vistica, H. Bokesch, S. Kenney, M. R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug Screening, J. Natl. Cancer. Inst., vol. 82, no. 13, July. 1990, Art. No 1107. https://doi.org/10.1093/jnci/82.13.1107
[2]. K. Higuchi, T. Watanabe, T. Tanigawa, Tominaga, K. Fujiwara, Y. Arakawa, T. Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori: A randomized controlled comparative trial with cimetidine, an H2-receptor antagonist, J. Gastroenterol. Hepatol., vol. 25, no. 01, April. 2010, Art. No S155. https://doi.org/10.1111/j.1440-1746.2010.06232.x
[3]. D. J. Connolly, D. Cusack, T. P. O’Sullivan and P. J. Guiry, Synthesis of quinazoliones and quinazolines, Tetrahedron., vol. 61, no. 43, October. 2005, Art. No 10153. http://dx.doi.org/10.1016/j.tet.2005.07.010
[4]. R. Rajput, A. P. Mishar, A review on biological activity of quinazoliones, Acadamic Sciences., vol. 04, no. 02. Janu. 2012, Art. No 66.
[5]. M. R Yadav, P. P. Naik, H. P. Gandhi, B. S. Chauhan, R. Giridhar, Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism, Bioorg. Med. Chem. Lett., vol. 23, no. 13, July. 2013, Art. No 3959. https://doi.org/10.1016/j.bmcl.2013.04.054
[6]. A. Hameed, M. Al-Rashida, M. Uroos, S. A. Ali, Arshia, M. Ishtiaq, K. M. Khan, Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016)- Expert Opin, Ther. Pat., vol. 28, no. 04, Feb. 2018, Art. No 281. https://doi.org/10.1080/13543776.2018.1432596.
[7]. T. P. Selvam, P. V. Kumar, Quinazoline marketed drugs, Res. Pharm., vol. 01, no. 01, 2015, Art. No 1-121.
[8]. P. N. Abida, M. Arpanarana, An updated review: newer quinazoline derivatives under clinical trial, Int. J. Pharm. Biol. Sci. Arch., vol. 02, no. 06, 2011, Art. No 1651.
[9]. A. W. Zahoor, S. P. Anup, M. Girish, B. Akanksha, J. M. Mubashir, K. G. Santosh, A. Viswanath, M. Fayaz, K. Ahmed, M. M. Dilip, Anticancer activity of a novel quinazolinone-chalcone derivative through cell cycle arrest in pancreatic cancer cell line. J. Solid Tumors., vol. 05, no. 02, June. 2015, Art. No 73. https://doi.org/10.5430/jst.v5n2p73
[10]. A W. Zahoor , K. G. Santosh, A.V. Subba, S. Sonia, M. Girish, B. Akanksha, K. Ashok, P. R. Sharma, K. Ahmed, B. Shashi, A novel quinazolinone chalcone derivative induces mitochondrial dependent apoptosis and inhibits PI3K/Akt/mTOR signaling pathway in human colon cancer HCT116 cells. Food Chem. Toxicol., vol. 87, Jan. 2016, Art. No 1. https://doi.org/10.1016/j.fct.2015.11.016
[11]. Nguyen V. Minh, Nguyen T. Thanh, Hoang T. Lien, Dinh T.P. Anh, Ho D. Cuong, Nguyen H. Nam, Pham T. Hai, Le Minh-Ngoc, Huong Le-Thi-Thu, Luu V. Chinh and Tran K. Vu. Design, Synthesis and Biological Evaluation of Novel Nhydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and cytotoxic agents. Anticancer Agents Med Chem., vol. 19, no. 12, Agust. 2019, Art. No 1543. https://doi.org/10.2174/1871520619666190702142654
[12]. P. Skehan, D. Storeng, A. Scudiero, J. Monks, D. McMahon, J. T. Vistica, H. Bokesch, S. Kenney, M. R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug Screening, J. Natl. Cancer. Inst., vol. 82, no. 13, July. 1990, Art. No 1107. https://doi.org/10.1093/jnci/82.13.1107